Back

Non-alcoholic fatty liver disease in patients with atrial fibrillation: a report from a global federated health network.

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Arrhythmias 8: atrial fibrillation Clinical EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Tommaso Bucci

University of Perugia, Perugia (Italy)

7 More presentations in this session

Presentation thumbnail
Prevention of venous thromboembolism after right heart-sided electrophysiological procedures: results of an EHRA survey
Doctor G. Mugnai (Verona, IT)
Abstract Slides Video
Presentation thumbnail
Left atrial posterior wall isolation during catheter ablation with the pulsed field ablation in patients with persistent atrial fibrillation
Doctor M. Schiavone (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Endocardial ablation of ganglionated plexus for the treatment of carotid sinus syndrome
Doctor C. Minguito Carazo (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
Useful aid or futile hassle - continuous rhythm monitoring following acute myocardial infarction
Mr L. Hamacher (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Long-term QT interval analysis for real world patients with Insertable cardiac monitors taking antiarrhythmic drugs
Ms M. Deus (Minneapolis, US)
Abstract Slides Video

Access the full session

Session thumbnail
Arrhythmias 8: atrial fibrillation

The Event

Event poster

EHRA 2024

7 April - 9 April 2024
You may be interested in
thumbnail
Congress Presentation
Risk of death, thrombotic and hemorrhagic events in patients with atrial fibrillation and systemic autoimmune diseases
thumbnail
Congress Presentation
Temporal trends of prescription rates, dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in patients with atrial fibrillation
thumbnail
Congress Presentation
Optimal adherence threshold to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation to reduce the risk of thromboembolism and death

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources